Laboratory markers of veno-occlusive disease in the course of bone marrow and subsequent liver transplantation.
Plasminogen activator inhibitor 1 (PAI-1) and amino-propeptide of type III procollagen (PIIINP) have been described as markers of hepatic veno-occlusive disease (VOD) after bone marrow transplantation (BMT). We determined these parameters in two patients undergoing BMT and subsequent liver transplantation due to VOD. Previously normal PAI-1 levels (maximum 30.0 ng/ml in patient 1, 23.7 ng/ml in patient 2) were elevated for the first time in both patients at the time of clinically diagnosed VOD on days 40 and 20, respectively (patient 1: 317.5 ng/ml; patient 2: 317.2 ng/ml). Levels remained elevated until liver transplantation was performed on days 79 and 41, respectively. Baseline levels (day -8) of aminopropeptide of type III collagen (patient 1: 4.44 microg/l; patient 2: 8.1 microg/l) peaked at the time of BMT in both patients (155.0 microg/l and 108.3 microg/l). After an intermittent decrease at the time of discharge on day 32, a second elevation was observed in patient 1 when she was readmitted and presented with typical signs of VOD on day 40. In patient 2, PIIINP levels remained high until VOD was diagnosed (day 20) and liver transplantation was performed. After liver transplantation, PAI-1 levels normalized in both patients and PIIINP levels declined. Both patients died due to infectious complications and multiorgan failure on days 141 and 101, respectively. Whereas the early rise of PIIINP did not correlate with the clinical onset of VOD, the results emphasise the relevance of PAI-1 for diagnosing VOD.
Salat
C
C
Med. Klinik III Klinikum Grosshadern, Ludwig-Maximilians-Universitat Munchen, Germany.
Holler
E
E
Wolf
C
C
Kolb
H J
HJ
Reinhardt
B
B
Pihusch
R
R
Krämling
H J
HJ
Heinemann
V
V
Haller
M
M
Hiller
E
E
D000208:Acute Disease; D000328:Adult; D000925:Anticoagulants / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D016026:Bone Marrow Transplantation; D004730:Endothelium, Vascular / Q000293:injuries / Q000378:metabolism; D005260:Female; D006493:Heparin / Q000627:therapeutic use; D006504:Hepatic Veno-Occlusive Disease / Q000097:blood* / Q000139:chemically induced / Q000175:diagnosis / Q000517:prevention & control / Q000601:surgery; D006801:Humans; D007951:Leukemia, Myeloid / Q000628:therapy; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000097:blood*; D017395:Plasminogen Activator Inhibitor 1 / Q000032:analysis*; D011347:Procollagen / Q000097:blood*; D012680:Sensitivity and Specificity; D019172:Transplantation Conditioning / Q000009:adverse effects*
D000925:Anticoagulants; D015415:Biomarkers; D010446:Peptide Fragments; D017395:Plasminogen Activator Inhibitor 1; D011347:Procollagen; C041876:procollagen Type III-N-terminal peptide; D006493:Heparin